SURMOUNT and the evidence base Tirzepatide's weight-management evidence comes largely from the SURMOUNT program ( The New England Journal of Medicine , 2022), with SURMOUNT-OSA (NEJM 2024) examining obstructive sleep apnea
Determine the appropriate medication hold window based on type
Nauck et al., 2020): Compounds based on the lizard-derived exendin-4 peptide and compounds based on the human GLP-1 peptide
It plays a central role in: Detoxifying toxins and heavy metals Supporting immune health and inflammation balance Regenerating other antioxidants (like vitamins C and E) Maintaining mitochondrial energy production Slowing the cellular aging process A low Glutathione Index may reflect oxidative stress or a depletion of antioxidant capacity
Retatrutide Availability Retatrutide is not yet approved by any regulatory body
Of these patients, a large proportion initiating oral semaglutide (36.1%) had no prior evidence of GLP-1-therapy use, suggesting that early adoption included a substantial proportion of patients new to using GLP-1 medications